Last reviewed · How we verify
Cohort 2 CTAP101 Capsules - 30µg
CTAP101 is a recombinant human parathyroid hormone-related protein (PTHrP) analogue.
CTAP101 is a recombinant human parathyroid hormone-related protein (PTHrP) analogue. Used for Osteoporosis.
At a glance
| Generic name | Cohort 2 CTAP101 Capsules - 30µg |
|---|---|
| Sponsor | OPKO Health, Inc. |
| Drug class | PTHrP analogue |
| Target | PTHrP |
| Modality | Small molecule |
| Therapeutic area | Bone disorders |
| Phase | Phase 2 |
Mechanism of action
CTAP101 works by mimicking the action of PTHrP, which is involved in bone metabolism. This leads to increased bone formation and density, potentially treating conditions associated with bone loss.
Approved indications
- Osteoporosis
Common side effects
- Nausea
- Headache
- Injection site reaction
Key clinical trials
- Safety/Efficacy Study of CTAP101 in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism (SHPT) (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cohort 2 CTAP101 Capsules - 30µg CI brief — competitive landscape report
- Cohort 2 CTAP101 Capsules - 30µg updates RSS · CI watch RSS
- OPKO Health, Inc. portfolio CI